Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injectable solution for intravenous use. It enhances magnetic resonance imaging of specific organs and vascular structures in patients undergoing diagnostic scans.

GNH USA supplies Multihance as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Multihance is used as a gadolinium‑based contrast agent for magnetic resonance imaging of several organ systems. - Central nervous system MRI: improves lesion detection and delineation by increasing signal intensity on T1‑weighted images. - Liver MRI: enhances detection and characterization of focal liver lesions, including hepatocellular carcinoma. - Cardiovascular MRI: provides high‑resolution images of cardiac chambers, myocardium, and vascular anatomy. - Magnetic resonance angiography (MRA): facilitates visualization of arterial and venous structures with improved contrast.

Adverse reactions to Multihance are generally related to its intravenous administration and the gadolinium chelate.

Common Side Effects: - Nausea: mild, transient feeling of stomach upset. - Headache: brief, mild to moderate intensity. - Injection site discomfort: pain or burning at the infusion site. - Warm sensation: transient feeling of warmth or flushing.

Serious or Rare Side Effects: - Allergic reaction: urticaria, rash, or anaphylaxis requiring emergency care. - Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment. - Severe hypotension: sudden drop in blood pressure following injection. - Cardiac arrhythmia: irregular heart rhythm observed in susceptible individuals.

When using Multihance, several safety considerations should be observed. - Renal function assessment: evaluate kidney function before administration, especially in patients with GFR <30 mL/min/1.73 m². - History of hypersensitivity: review prior reactions to gadolinium agents or contrast media. - Pregnancy: use only if clearly needed, as safety data are limited. - Breastfeeding: consider risk/benefit; limited data on excretion in milk. - Concomitant nephrotoxic drugs: monitor closely when used with agents that may affect renal function. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Severe renal impairment agents: co‑administration with other gadolinium agents increases risk of NSF. - High‑dose calcium supplements: may interfere with gadolinium binding, potentially increasing free gadolinium. - Iron chelators: can displace gadolinium from its chelate, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: may affect renal clearance, requiring monitoring of kidney function. - ACE inhibitors/ARBs: combined effect on renal perfusion may necessitate closer observation. - Antihistamines: may mask early signs of an allergic reaction, requiring vigilance.